Industry Revenues:

• Pharmaceutical Products: 60%
• Biotechnology: 25%
• Health Services: 15%

TOP 3 Markets:

1. China: 50%
2. USA: 20%
3. Europe: 15%

Pacific Shuanglin Bio-pharmacy Co., Ltd. generates the majority of its revenues from the sale of pharmaceutical products, followed by biotechnological solutions and health services. The Chinese market is the most significant revenue contributor, attributed to strong local presence and demand. The USA and Europe follow as important international markets served through strategic partnerships and expansions.

Production Sites: China (Main Site)

Pacific Shuanglin Bio-pharmacy Co., Ltd. mainly produces its products in China. The company strategically distributes its production facilities throughout the country to benefit from the advantages of local infrastructure and proximity to raw material suppliers. These sites are typically located in industrial centers that provide good access to logistics and transportation networks.

In the future, the company may also expand or diversify its production capacities to meet the growing market demands.

Focus on Research and Development: 10% of revenue (2025)

Expansion into International Markets: Planned market entries in Southeast Asia and Europe (2026)

Pacific Shuanglin Bio-pharmacy Co., Ltd. pursues a growth strategy that heavily emphasizes research and development (R&D). The company invests approximately 10% of its revenue in R&D to develop innovative pharmaceutical products and expand its product pipeline.

Additionally, the company plans to expand its presence in international markets. In particular, Pacific Shuanglin aims to enter the markets of Southeast Asia and Europe in the coming years. This expansion will be supported by strategic partnerships and potential acquisitions to facilitate market entry and leverage local market knowledge.

Through these measures, the company aims to increase its market share both nationally and internationally, and to secure sustainable long-term growth.

Main raw materials: Pharmaceutical active ingredients, excipients
Countries of origin: China, India, Germany

Pacific Shuanglin Bio-pharmacy Co., Ltd. mainly imports pharmaceutical active ingredients and excipients needed for the production of their products. The main supplier countries are China and India, which are considered significant producers of pharmaceutical raw materials. Germany is also utilized as a source for specialized pharmaceutical materials, especially high-quality excipients.

This import strategy enables the company to benefit from the competitive prices and high quality of raw materials from these countries. Diversifying the supplier countries also helps to minimize the risk of supply shortages.

Market Share: Estimated 8% (2026, based on industry comparisons)

Research & Development (R&D) Expenses: 12% of revenue (2025)

Patents: Over 50 active patents (2025)

Pacific Shuanglin Bio-pharmacy Co., Ltd. has a moderate competitive advantage in the biopharmaceutical industry. The company invests significantly in research and development, as highlighted by the R&D expenses of 12% of revenue in 2025. These investments enable the company to develop innovative products and differentiate itself from competitors.

Another advantage is the extensive portfolio of over 50 active patents, providing the company with protection against imitators and strengthening its position in the market. However, the market share of approximately 8% indicates that the company operates in a highly fragmented and competitive market.

To further enhance its competitive advantage, the company could strengthen its market presence through strategic partnerships and international expansion.

Institutional Investor Share: Estimated 25% (2026)
Insider Buys/Sells: No significant transactions reported (2026)

The institutional investor share in Pacific Shuanglin Bio-pharmacy Co., Ltd. is estimated to be around 25%. This suggests that a quarter of the shares are held by institutional investors such as investment funds, pension funds, and other large financial institutions.

Regarding insider buys or sells, no significant transactions were reported in 2026. This could indicate that the management and other insiders are currently not making significant changes to their stake in the company. Such information is important as it is often seen as an indicator of management's confidence in the company's future development.

Market share of Pacific Shuanglin Bio-pharmacy Co., Ltd.: Estimated around 3-5% (2026)

Top competitors and their market share:

1. Sinopharm Group Co., Ltd.: around 15%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: around 12%
3. China Resources Pharmaceutical Group Ltd.: around 10%
4. CSPC Pharmaceutical Group Ltd.: around 8%
5. Jiangsu Hengrui Medicine Co., Ltd.: around 7%
6. Huadong Medicine Co., Ltd.: around 6%
7. Sino Biopharmaceutical Limited: around 5%
8. Pacific Shuanglin Bio-pharmacy Co., Ltd.: around 3-5%

Pacific Shuanglin Bio-pharmacy Co., Ltd. has a relatively small market share compared to the leading companies in the industry. The company's moat could be based on specialized products or niche markets, but it is less pronounced compared to larger competitors like Sinopharm or Shanghai Pharmaceuticals.

Larger companies often have a significant advantage due to their extensive resources, wider product ranges, and stronger distribution networks. These factors contribute to a stronger moat, allowing them to defend and expand market share more effectively. However, Pacific Shuanglin could gain a competitive advantage through innovation or specialized services.

Revenue Growth: 10% (2025)
Research and Development Expenses: 15% of revenue (2025)
Market Share in the Biopharmaceutical Industry: 5% (2025)

Pacific Shuanglin Bio-pharmacy Co., Ltd. achieved a revenue growth of 10% in 2025, attributed to successful expansion into new markets and the introduction of innovative products. The company is heavily investing in research and development, accounting for 15% of its revenue. These investments indicate a strategic focus to remain competitive in the long term and develop new products.

With a 5% market share in the biopharmaceutical industry, the company holds a significant position, indicating a strong market presence. These factors, combined with innovation and strategic focus, make the stock a potentially good investment for investors interested in long-term growth.

However, it is important to also consider external factors such as regulatory changes and market developments that could impact future performance.

Dividend Yield: 3.2% (2025)
Dividend History: Continuous payout over the last 5 years

Pacific Shuanglin Bio-pharmacy Co., Ltd. reported a dividend yield of 3.2% in 2025. The company has consistently distributed dividends over the past five years, indicating a certain reliability in its dividend policy.

The consistency of dividend payments suggests that the company has stable financial foundations and aims to regularly return capital to shareholders. However, analysts may continue to monitor the future dividend policy in the context of the overall company strategy and market conditions.